Senores Pharmaceuticals, an established Indian pharmaceutical company with a growing footprint in generics and essential drugs, has announced the acquisition of Apnar Pharma in a transaction valued at approximately ₹91 crore. The move is intended to strengthen Senores’ product portfolio, deepen its market penetration and accelerate growth across domestic and institutional channels.

Apnar Pharma brings to the table a range of well-positioned generic formulations and an active distribution network that complements Senores’ existing strengths. By incorporating these assets, Senores expects to broaden its therapeutic reach and deliver enhanced value to patients, healthcare providers and channel partners.

According to leadership at Senores, the acquisition supports the company’s strategic roadmap of building scale, improving operational synergies and expanding into new markets. The blended portfolio and distribution capabilities are expected to boost competitiveness, especially in high-demand categories such as chronic care medications and widely used generic drugs.

Market analysts view the acquisition as a timely opportunity for Senores to consolidate its presence in the generics segment, leverage complementary product mixes, and strengthen its supply chain and delivery capabilities. This aligns with broader industry trends where mid-sized domestic pharmaceutical firms are investing in strategic M&A to accelerate scale and market leadership in an increasingly competitive environment.